Secukinumab Reduces Psoriasis Itch and Restores Nerve Architecture, Study Finds
Germany: A recent study, PSORITUS, revealed the efficacy of Secukinumab (SEC), a biologic therapy, in significantly reducing pruritus (itch) associated with psoriasis while regenerating the cutaneous nerve architecture and improving skin health. The double-blind, placebo-controlled, Phase IIIb randomized withdrawal trial highlights the multifaceted benefits of SEC for individuals with psoriasis, a chronic inflammatory skin condition.
"SEC outperformed placebo by effectively reducing pruritus intensity, restoring clinical normalcy to skin lesions, and reversing histopathological abnormalities. Additionally, SEC promoted neuroanatomical recovery, which remained stable even after treatment withdrawal," the researchers wrote in Acta Dermato-Venereologica.
Pruritus in psoriasis was once thought to be less prevalent than it is, yet it poses a significant burden on patients. While Secukinumab, a monoclonal anti-interleukin-17A antibody, is known to effectively control the signs of psoriasis, its impact on pruritus and cutaneous neuroanatomy has not been fully understood.
To fill this knowledge gap, Lina Renkhold, Department of Dermatology, University Hospital Münster, Münster, Germany; Center for Chronic Pruritus, University Hospital Münster, Münster, Germany, and colleagues aimed to assess the superiority of SEC treatment over placebo in reducing pruritus intensity, measured by the visual analog scale (VAS). Additionally, the study examined the relationship between treatment and the progression of pruritus in relation to the absolute Psoriasis Area Severity Index (PASI) score and changes in cutaneous histopathology and neuroanatomy.
For this purpose, the researchers administered open-label SEC 300 mg subcutaneously at regular intervals until week 16. Patients who achieved a ≥98% reduction in PASI (PASI ≥98) were then randomized to receive either placebo or SEC treatment until week 32. Punch biopsies were obtained from lesional psoriatic (at baseline, weeks 16, and 32) and non-lesional (at baseline) skin for histopathological and neuroanatomical analysis.
The study led to the following findings:
- VAS scores showed significant improvement after open-label SEC treatment but relapsed upon placebo (29.92 ± 33.8) compared to SEC (12.30 ± 22.6).
- After SEC-induced improvement in PASI, histopathology, marker expression, and neuroanatomy, relapse was observed upon treatment discontinuation in all parameters except for neuroanatomy.
The PSORITUS study emphasizes the potential of Secukinumab potential as a comprehensive treatment for psoriasis, addressing both visible symptoms and underlying structural abnormalities.
"These results pave the way for future research into IL-17A inhibitors and their broader implications in dermatological and neurological disorders. For psoriasis patients, SEC offers renewed hope for improved skin health and lasting relief from the discomfort of pruritus," the researchers concluded.
Reference:
Renkhold, L., Pereira, M. P., Loser, K., Metze, D., Baeumer, D., Melzer, N., … Ständer, S. (2024). Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study. Acta Dermato-Venereologica, 104, adv40737. https://doi.org/10.2340/actadv.v104.40737
